AC Immune SA (ACIU) vs Compass Therapeutics (CMPX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
AC Immune SA (ACIU) has outperformed Compass Therapeutics (CMPX) over the past year, losing 17.6% versus a loss of 79.8%. Over five years, ACIU leads with a -60.4% price change compared with -73.5% for CMPX. AC Immune SA is the larger company by market cap ($237.6 million vs $154.9 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | CMPX |
|---|---|---|
| Share price | $2.39 | $0.86 |
| Market cap | $237.63M | $154.88M |
| 1-day change | -2.45% | -4.09% |
| YTD return | -23.89% | -83.99% |
| 1-year return | -17.59% | -79.81% |
| 5-year return | -60.36% | -73.54% |
| Forward P/E | 3.98 | — |
| EPS (TTM) | $-0.54 | $-0.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | — | $-66.49M |
| 52-week high | $4.00 | $6.88 |
| 52-week low | $2.10 | $0.822 |
| Distance from 52-week high | -40.25% | -87.50% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +261.51% | +533.72% |
| Average volume | 198.18K | 4.30M |
| Shares outstanding | 99.43M | 180.09M |
| Employees | 90 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACIU has outperformed CMPX by 62.2 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Healthcare · Biotechnology · 90 employees
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Healthcare · Biotechnology · 39 employees
ACIU vs CMPX FAQ
Which is bigger, AC Immune SA or Compass Therapeutics?
AC Immune SA (ACIU) is larger, with a market capitalization of $237.63M compared with $154.88M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, ACIU or CMPX?
ACIU returned -17.59% over the past 12 months, compared with -79.81% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Compass Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.